CENTESSA PHARMACEUTICALS - Asset Resilience Ratio
CENTESSA PHARMACEUTICALS (260) has an Asset Resilience Ratio of 33.37% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 260 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how CENTESSA PHARMACEUTICALS's Asset Resilience Ratio has changed over time. See CENTESSA PHARMACEUTICALS (260) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down CENTESSA PHARMACEUTICALS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 260 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €214.16 Million | 33.37% |
| Total Liquid Assets | €214.16 Million | 33.37% |
Asset Resilience Insights
- Very High Liquidity: CENTESSA PHARMACEUTICALS maintains exceptional liquid asset reserves at 33.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CENTESSA PHARMACEUTICALS Industry Peers by Asset Resilience Ratio
Compare CENTESSA PHARMACEUTICALS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
| No industry peers found with asset resilience data. | ||
Annual Asset Resilience Ratio for CENTESSA PHARMACEUTICALS (2022–2025)
The table below shows the annual Asset Resilience Ratio data for CENTESSA PHARMACEUTICALS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 33.93% | €233.28 Million ≈ $272.73 Million |
€687.50 Million ≈ $803.75 Million |
+16.78pp |
| 2024-12-31 | 17.16% | €98.96 Million ≈ $115.69 Million |
€576.80 Million ≈ $674.34 Million |
-18.52pp |
| 2023-12-31 | 35.68% | €128.52 Million ≈ $150.25 Million |
€360.25 Million ≈ $421.17 Million |
-- |
| 2022-12-31 | 0.00% | €0.00 ≈ $0.00 |
€444.31 Million ≈ $519.44 Million |
-- |
About CENTESSA PHARMACEUTICALS
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hyperso… Read more